Evidence map›Paper›PMID 36978872›Full record

ReviewAntioxidants (Basel, Switzerland)2023

Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review.

Jan Lazur, Kamil Hnatyk, Katarzyna Kała, Katarzyna Sułkowska-Ziaja, Bożena Muszyńska

Open access · goldFull text readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. TheFoods (Basel, Switzerland) · 2026
    Article
  5. Anti-Stress Effects ofNutrients · 2025
    Article
  6. Review
  7. Biological Activities of Ethanol Extracts ofFoods (Basel, Switzerland) · 2024
    Article
  8. Review
  9. Wild Mushrooms: A Hidden Treasure of Novel Bioactive Compounds.International journal of analytical chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jan LazurDepartment of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688 Kraków, Poland.
Kamil HnatykDepartment of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688 Kraków, Poland.ORCID 0009-0009-5203-5313
Katarzyna KałaDepartment of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688 Kraków, Poland.ORCID 0000-0001-8354-211X
Katarzyna Sułkowska-ZiajaDepartment of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688 Kraków, Poland.ORCID 0000-0002-7325-9254
Bożena MuszyńskaDepartment of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688 Kraków, Poland.ORCID 0000-0002-5007-1486
Jagiellonian University · PL

Funding

"Excellence Initiative - Research University" at the Jagiellonian University 06/IDUB/2019/94Polish Ministry of Science and Higher Education N42/DBS/000271
6 · The paper itself

Abstract

Major Depression Disease is a common mental illness that affects more than 322 million people worldwide and it is one of the leading causes of mental and physical disability. The etiology of depression is a complex interplay of psychological, social, and biological factors. Currently, psychopharmacotherapy is based mainly on the monoamine theory, which states that depression is caused by an insufficient level of monoamines such as serotonin, norepinephrine, and/or dopamine. Due to the relatively low efficacy of the typical antidepressant and the high prevalence of treatment-resistant depression (~30%), seeking new ways of prophylaxis, adjuvant therapy, or novel compounds with antidepressant activity, is a priority. According to studies that analyzed mushroom consumption patterns and depression prevalence, it was concluded that mushroom ingestion lowers the odds of depression. Medicinal mushrooms are considered functional foods because of their ability to synthesize and accumulate different types of metabolites, which enhance their health-promoting properties. The review aims to explain the antidepressant activity of edible/medicinal mushrooms by elucidating the mechanism from different perspectives: edible mushrooms as a source of serotonin precursors and psilocybin as a rapid-acting antidepressant. These compounds exhibit anti-neuroinflammatory and antioxidant activities that impact neurotrophin expression, the neurogenesis process, and influence on the gut-brain axis.

Indexed as

antioxidant activityBDNFgut–brain axisL–tryptophanneurogenesisneuroinflammationpsilocybin

Identifiers

PMID36978872
PMCPMC10044934
OpenAlexW4323047575

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read87
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.